Page 59 - Renato Martins Araújo_M
P. 59

58





                     ISLAMI, F.; MOREIRA, D.M.; BOFFETTA, P.; FRREDLAND, S.J. A systematic
                     review anda meta-analysis of tobacco use and prostate cancer mortality and
                     incidence in porspective cohort studies. Eur Urol, v. 66, n. 6, p. 1054-64, Dec.
                     2014. Disponivel em: <https://www.ncbi.nlm.nih.gov/pubmed/25242554>. Acesso
                     em: 31 mar. 2017.


                     JAIN, S.; SAXENA, S.; KUMAR, A. Epidemiology of prostate cancer in India. Meta
                     Gene, v. 2, p. 596–605, 2014. Disponível em: <https://www.ncbi.nlm.nih.gov/pmc/
                     articles/PMC4287887/>. Acesso em: 5 dez. 2016.


                     JEMAL, A.; SIEGEL, R.; XU, J.; WARD, E. Cancer statistics. Cancer J Clin, v. 60.
                     p. 277-300, 2010. Disponível em: <https://www.ncbi.nlm.nih.gov/pubmed
                     /20610543>. Acesso em: 12 jan. 2017.

                     JURADO, R.S.; CARVALHO, C.; ROSA, D.; COSTA, F.; GÓIS, J., ARAÚJO, A.;
                     FRANÇA, L.; OLIVEIRA, S. Câncer de próstata: epidemiologia, fatores de risco,
                     diagnóstico e tratamento. XVIII Encontro nacional dos grupos PET – ENAPET.
                     Recife-PE, UFPE/UFRPE, 1 -  6 out. 2013.-


                     KRISTAL, A.R.; CHEN, C.; TANGEN, C.M.; GOODMAN, F.J.; ETZIONI, R.;
                     THOMPSON, I.M. Associations of Demographic and Lifestyle Characteristics with
                     Prostate-Specific Antigen (PSA) Concentration and Rate of PSA Increase.
                     American Cancer Society, v. 106, n. 2, p. 320-328, 2006. Disponível em:
                     <http://onlinelibrary.wiley.com/doi/10.1002/cncr.21603/abstract>. Acesso em: 15
                     abr. 2015.


                     KRUMHOLTZ, J.S.; CARVALHAL, G.F.; RAMOS, C.G.;  SMITH,
                     D.S.; THORSON, P.; YAN, Y.; HUMPHREY, P.A.; ROEHL, K.A.; CATALONA,
                     W.J. Prostate specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is
                     associated with favorable pathologic tumor features. Urology, v. 60, p. 469-74,
                     2002. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/12350486>. Acesso
                     em: 15 abr. 2015.


                     KRYVENKO, O.N.; EPSTEIN, J.I. Prostate Cancer Grading: A Decade After the
                     2005 Modified Gleason Grading System. Arch Pathol Lab Med, v. 140, p. 1140-
                     1152, 2016. Disponível em: <http://www.archivesofpathology.org/ doi/pdf/
                     10.5858/arpa.2015-0487-SA?code= coap-site>. Acesso em: 12 mar. 2017.

                     LIMA, C.A.; SILVA, A.M.; KUWANOC, A.Y.; Margareth Rose Uchôa RANGELA,
                     M.R.U.; MACEDO-LIMA, M. Trends in prostate cancer incidence and mortality in a
                     mid-sized Northeastern Brazilian city. Revista da Associação Médica Brasileira,
                     v. 59, n. 1, p. 15-20, 2013. Disponível em: <http://www.sciencedirect.com/science/
                     article/pii/S2255482313704247> Acesso em: 02 maio 2015.
   54   55   56   57   58   59   60   61   62   63   64